Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment

ONC201 is a first-in-class, orally active antitumor agent that upregulates cytotoxic TRAIL pathway signaling in cancer cells. ONC201 has demonstrated safety and preliminary efficacy in a first-in-human trial in which patients were dosed every 3 weeks. We hypothesized that dose intensification of ONC...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Invest
Prif Awduron: Wagner, Jessica, Kline, C. Leah, Zhou, Lanlan, Campbell, Kerry S., MacFarlane, Alexander W., Olszanski, Anthony J., Cai, Kathy Q., Hensley, Harvey H., Ross, Eric A., Ralff, Marie D., Zloza, Andrew, Chesson, Charles B., Newman, Jenna H., Kaufman, Howard, Bertino, Joseph, Stein, Mark, El-Deiry, Wafik S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Clinical Investigation 2018
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5983321/
https://ncbi.nlm.nih.gov/pubmed/29533922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI96711
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg